Aids 2024, the 25TH international aids conference, munich, germany, and virtually 22-26 july 2024
Ended Project Grant Awarded Last action
- Award ID
- R13AI183912
- Recipient
-
IAS UEI TQ45HEKL1B43
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $200,000
Award facts
- Assistance listing
- 93.310 Trans-NIH Research Support
- Completion date
- Funding agency
- Office of the Director National Institutes of Health, Department of Health and Human Services
- Place of performance
- Washington, DC, USA
Award details come from USAspending.gov.
Description
- Abstract
- Without significant additional political leadership, investment and further scientific advance, the global response to HIV/aids is not on track to achieve the 2030 goal of ending aids as a public health threat. This is due to continued high rates of incident HIV infection in multiple communities, populations, countries, and regions. While HIV science has made remarkable advances, implementation of highly effective prevention and treatment options remains challenging. Taken together, these realities underscore that the HIV response must be global to succeed, that HIV research and training efforts must also be global and multidisciplinary, and that actors in all sectors of the HIV response are needed to address our shared goal of reducing HIV as a threat to global health and individual wellbeing. To respond to this imperative, the 25TH international aids conference, aids 2024, will convene the HIV community in munich, germany, and virtually in july 2024. Aids 2024 will bring together clinicians and people living with HIV, community leaders and policy makers, basic scientists, junior investigators, donors, journalists, and experts from law, policy and program implementation. This diversity is essential to revitalizing the HIV response, since multi-sectoral and multi-disciplinary work is needed. Munich was also selected as host city to bring a specific focus on central and eastern europe, including ukraine and the russian federation, where the HIV epidemic continues to expand, driven by a lack of access to health services for key populations and exacerbated by the disruption and instability of the war in ukraine, mass migration and faltering economies. Aids 2024 aims to: 1. Accelerate scientific discovery to drive innovation across the HIV prevention and treatment cascades, including pathogenesis, transmission, CO-morbidities, vaccines, and cure; long-acting oral and injectable treatment and prevention technologies, including rings for prevention; integrated and differentiated models of care; and analyses of structural and economic determinants of health. 2. Advance core components of implementation science research that address the challenges and opportunities of implementing novel prevention and treatment modalities in different populations and contexts, including implementation of long-acting antiretrovirals for prevention and treatment, and in settings of conflict and displacement. 3. Address HIV vulnerability and determinants of disease progression among key and vulnerable populations, including novel interventions and implementation science to reduce stigma and discrimination, including intersectional stigmas of HIV, homophobia, transphobia, and ethnic and racial disparities. 4. Draw attention to enduring gaps in the HIV response, such as areas where greater investment is needed in research and person-centered service delivery, and where the needs of communities remain neglected. 5. Explore complex dynamics of the still expanding HIV epidemic in central and eastern europe, including structural barriers preventing uptake of services by key and vulnerable populations and the impact of the war in ukraine. The scientific program will consist of six tracks: track a/basic and translational research; track b/clinical research; track c/epidemiology and prevention research; track d/social and behavioral research; track e/implementation research, economics, systems and synergies; and track f/political research, law, policy and human rights. Main topics, challenges and developments to be addressed in each track are described below. While the scientific program of the conference is developed by international members of track committees representative of different disciplines and areas of science, cross-cutting aspects will be covered in plenary talks that also connect the scientific tracks with community and policy perspectives. Additionally, bridging sessions are designed to cut across at least two of the scientific tracks to provide opportunities for multi-disciplinary, multi-perspective dialogues. A particular emphasis will be placed on ensuring interaction between on-site and virtual conference delegates in q & a and discussion sessions through the use of advanced conferencing technology. Access and diversity will remain key guiding principles at aids 2024, with large scholarship and youth programs to strengthen engagement and capacities of the next generation of researchers, clinicians, educators, and advocates. The conference will be fully hybrid with all conference sessions accessible online live and on demand.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $100,000 | |
| Original award | $100,000 |
Quick answers
Who received award R13AI183912?
R13AI183912 was awarded to IAS by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on April 19, 2024.
How much is award R13AI183912 worth?
$200,000 has been obligated on R13AI183912.
Which agency awarded R13AI183912?
National Institute of Allergy and Infectious Diseases (National Institutes of Health) awarded R13AI183912, with funding from Office of the Director (National Institutes of Health).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award